CLINICAL_TRIALS
trial_result
· 2025-02-06
Clinical Trial Update: Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors [Phase 2]
Summary
Phase 2 trial evaluating Ivosidenib in combination with Nivolumab for IDH1-mutant tumors, including glioma, has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jason J. Luke, MD | Conditions: Advanced Solid Tumor, IDH1 Mutation | Phase 2 | Status: COMPLETED | Results posted: 2025-02-06